Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

2.
3.

Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3.

Rubenstein M, Hollowell CM, Guinan P.

Med Oncol. 2013;30(3):599. doi: 10.1007/s12032-013-0599-3. Epub 2013 May 16.

PMID:
23677569
4.

In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides.

Rubenstein M, Hollowell CM, Guinan P.

Ther Adv Urol. 2011 Apr;3(2):51-7. doi: 10.1177/1756287211400493.

5.

Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.

Rubenstein M, Hollowell CM, Guinan P.

Med Oncol. 2012 Sep;29(3):2284-90. doi: 10.1007/s12032-011-0097-4. Epub 2011 Oct 30.

PMID:
22038727
7.

No compensation in VEGF expression follows antisense suppression of BCL-2 activity.

Rubenstein M, Hollowell CM, Guinan P.

In Vivo. 2012 Nov-Dec;26(6):937-40.

PMID:
23160675
9.
10.

Bax expression remains unchanged following antisense treatment directed against BCL-2.

Rubenstein M, Hollowell CM, Guinan P.

Med Oncol. 2011 Sep;28(3):852-8. doi: 10.1007/s12032-010-9543-y. Epub 2010 Apr 27.

PMID:
20422317
11.

Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation.

Rubenstein M, Chou P, Mirochnik Y, Guinan P.

Med Oncol. 1997 Mar;14(1):23-9.

PMID:
9232607
12.
13.

Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.

Culig Z.

J Cell Physiol. 2016 Feb;231(2):270-4. doi: 10.1002/jcp.25099. Review.

PMID:
26201947
14.

No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.

Rubenstein M, Hollowell CM, Guinan P.

In Vivo. 2013 Mar-Apr;27(2):251-6.

PMID:
23422486
15.
16.
17.

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.

Rubenstein M, Tsui P, Guinan P.

Med Oncol. 2010 Sep;27(3):592-9. doi: 10.1007/s12032-009-9254-4. Epub 2009 Jun 16.

PMID:
19533419
18.

Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.

Rubenstein M, Hollowell CM, Guinan P.

Med Oncol. 2012 Jun;29(2):835-41. doi: 10.1007/s12032-011-9977-x. Epub 2011 May 15.

PMID:
21573974
20.

Expression and function of androgen receptor coactivators in prostate cancer.

Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. Epub 2004 Dec 19. Review.

PMID:
15663989

Supplemental Content

Support Center